Inovio Pharma (INO) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Maxim Group Upgrades Inovio Pharmaceuticals (INO) to Buy
March 16, 2017 7:28 AM EDTMaxim Group upgraded Inovio Pharmaceuticals (NASDAQ: INO) from Hold to Buy with a price target of $10.00.
Analyst Jason McCarthy highlighted:
Inovio reported YE16 with $35M in revenue (grants, collaborations) and $112M in operating expenses for a net loss of $74M. The company ended the year with $105M in cash. We expect Inovio will continue to receive grant and collaborative revenue in 2017 which will partially offset operating expenses.... More